Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer
Authors:
- Daniele VergaraDaniele Vergara
- Claudia BellomoCBClaudia Bellomo
- Xingcai ZhangXZXingcai Zhang
- Viviana VergaroViviana Vergaro
- Andrea TinelliAndrea Tinelli
- Vito LorussoVLVito Lorusso
- Ross RinaldiRoss Rinaldi
- Yuri M. LvovYLYuri M. Lvov
- Stefano LeporattiStefano Leporatti
- Michele MaffiaMMMichele Maffia
- 1 August 2012
- journal article
- research article
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 8 (6) , 891-899
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Anti-MUC1 Monoclonal Antibody (C595) and Docetaxel Markedly Reduce Tumor Burden and Ascites, and Prolong Survival in an in vivo Ovarian Cancer ModelPLOS ONE, 2011
- Novel Aptamer-Nanoparticle Bioconjugates Enhances Delivery of Anticancer Drug to MUC1-Positive Cancer Cells In VitroPLOS ONE, 2011
- Converting Poorly Soluble Materials into Stable Aqueous NanocolloidsLangmuir, 2010
- TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancerOncogene, 2009
- A common cofilin activity cycle in invasive tumor cells and inflammatory cellsJournal of Cell Science, 2009
- Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cellsCancer Letters, 2009
- Mucins in ovarian cancer diagnosis and therapyJournal of Ovarian Research, 2009
- Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast CancerJournal of Clinical Oncology, 2008
- Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2Cancer Research, 2008
- Exploiting the PI3K/AKT Pathway for Cancer Drug DiscoveryNature Reviews Drug Discovery, 2005